Continuation of Partnership in the Development of KAHR-102

20th June 2011 | Proteins

Under the terms of the agreement, RecipharmCobra Biologics will continue to advance KAHR-102 for future pre-clinical and clinical testing using RecipharmCobra’s maxXpress service.

RecipharmCobra Biologics, the international manufacturer of biopharmaceuticals, and KAHR Medical Ltd., that develops novel drugs based on the Signal Converter Proteins (SCP) technology for the treatment of cancer and autoimmune diseases, announced today a continuation of their partnership agreement.

Peter Coleman, General Manager at RecipharmCobra Biologics, said: “We are extremely pleased that our development partnership continues with KAHR. Our partnership with KAHR has strengthened over the years due to the strong working relationship between both technical teams and we look forward to its continuation. It is an endorsement of the working relationship we invest in with our customers.”

Dr. Noam Shani, CEO of KAHR Medical, said “It has been a pleasure working with RecipharmCobra Biologics over the years and we have enjoyed the interaction and responsiveness of its team. We hope to build on our successful partnership with the fast-track development of KAHR-102.”

comments powered by Disqus
In order to provide complete functionality, this web site needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site. It is recommended that you allow all cookies. Allow all cookies